NLNK Lumos Pharma Inc.

NEWLINK GENETICS NOTIFICATION: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In NewLink Genetics Corporation (NLNK) To Contact The Firm

NEW YORK--(BUSINESS WIRE)--

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at NewLink Genetics Corporation (“NewLink” or the “Company”) (NASDAQGM:NLNK).

The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that NewLink’s immunotherapy drug, indoximod, was not showing a meaningful benefit in its Phase 2 trial for patients with advanced melanoma.

Since the results of the Phase 2 trial were announced on April 4, 2017, the stock has dropped more than 10% on unusually heavy volume.

Request more information now by clicking here: www.faruqilaw.com/NLNK. There is no cost or obligation to you.

Take Action

If you invested in NewLink stock or options between October 25, 2016 and April 3, 2017 and would like to discuss your legal rights, visit www.faruqilaw.com/NLNK. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to [email protected]. Faruqi & Faruqi, LLP also encourages anyone with information regarding NewLink’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

EN
04/04/2017

Underlying

NLNKLumos Pharma Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Lumos Pharma Inc.

 PRESS RELEASE
Free
NLNK Lumos Pharma I...

Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directo...

Lumos Pharma Appoints Joseph S. McCracken, DVM, MS to Board of Directors Rick Hawkins, CEO, appointed Chairman of the Board AUSTIN, Texas, March 30, 2020 (GLOBE NEWSWIRE) -- (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, has announced the appointment of Joseph S. McCracken, DVM, MS to the company's Board of Directors, effective March 23, 2020. Dr. McCracken has extensive experience in the pharmaceutical and biotechnology industry, with prominent roles in business development, commercial development, and positions as board member for s...

March 30, 2020 1 EN
 PRESS RELEASE
Free
NLNK Lumos Pharma I...

NewLink Genetics Stockholders Approve Merger with Lumos Pharma

NewLink Genetics Stockholders Approve Merger with Lumos Pharma - Combined company, Lumos Pharma, Inc., to trade on Nasdaq under the stock symbol “LUMO” - Phase 2b trial expected to be initiated mid-2020 evaluating oral therapeutic candidate LUM-201 (ibutamoren) in Pediatric Growth Hormone Deficiency (PGHD) - Projected combined cash on March 31, 2020 in excess of $80 million expected to be sufficient to fund company through Phase 2b trial in PGHD data read-out AUSTIN, Texas and AMES, Iowa, March 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (Lumos Pharma) and NewLink Genetics Corpora...

March 18, 2020 1 EN
 PRESS RELEASE
Free
NLNK Lumos Pharma I...

NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial R...

NewLink Genetics Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update Special Meeting of Stockholders set for March 17, 2020 for vote on proposed merger of NewLink Genetics and Lumos Pharma AMES, Iowa, Feb. 28, 2020 (GLOBE NEWSWIRE) -- (NASDAQ:NLNK) today announced financial results for the fourth quarter and full year ended December 31, 2019, and provided an update on corporate activities. “We continue to focus our work toward the anticipated completion of our proposed merger with Lumos Pharma,” stated Carl Langren, Chief Financial Officer, and me...

February 28, 2020 1 EN
Free Trial
NLNK Lumos Pharma I...

NEWLINK GENETICS CORP. suffers a double requalification, which weighs ...

The independent financial analyst theScreener just downgraded the general evaluation of NEWLINK GENETICS CORP. (US), active in the Biotechnology industry. As regards its fundamental valuation, the title loses a star(s) and now shows 0 out of 4 stars. Its market behaviour is also negatively reassessed and may be considered as risky. theScreener believes that this double requalification keeps the title under pressure and justifies an overall rating downgrade to Negative. As of the analysis date Ja...

NLNK LUMOS PHARMA INC.
01/25/20 January 25, 2020 6 EN
 PRESS RELEASE
Free
NLNK Lumos Pharma I...

NewLink Genetics Announces Exclusive Worldwide License Agreement with ...

NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207 AMES, Iowa, Dec. 23, 2019 (GLOBE NEWSWIRE) -- (NASDAQ:NLNK) announced today that the company has entered into an exclusive worldwide license agreement with Ellipses Pharma Limited (Ellipses) for the development of and rights to commercialize NLG207 (formerly CRLX101), a nanoparticle formulation of the topoisomerase 1 inhibitor camptothecin. This license agreement signed by NewLink Genetics and Ellipses is effective as of December 17, 2019. Und...

December 23, 2019 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch